Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Medical approaches to primary hyperparathyroidism.

¹Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

Endocrinology and Metabolism Clinics of North America

|October 18, 2000

Summary

Medical therapy effectively treats primary hyperparathyroidism, especially recurrent cases and parathyroid cancer. New calcimimetic agents offer a novel approach by directly reducing parathyroid hormone secretion.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

FGF23, hypophosphatemia, and rickets: has phosphatonin been found?

Proceedings of the National Academy of Sciences of the United States of America·2001

Same author

Local and systemic control of the osteoblast.

The Journal of clinical investigation·2001

Same author

The parathyroid hormone-related protein.

Endocrinology and metabolism clinics of North America·2000

Same author

The physiology of parathyroid hormone-related protein.

The New England journal of medicine·2000

Same author

Bone-selective analogs of human PTH(1-34) increase bone formation in an ovariectomized rat model.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·1996

Same author

Parathyroid hormone-related protein is induced during lethal endotoxemia and contributes to endotoxin-induced mortality in rodents.

Molecular medicine (Cambridge, Mass.)·1996

Area of Science:

Endocrinology
Metabolic Bone Disease

Background:

Primary hyperparathyroidism involves overactive parathyroid glands, leading to elevated calcium levels.
Medical therapy is indicated for specific patient groups, including those with acute, recurrent, or malignant disease.

Purpose of the Study:

To review current and emerging medical therapies for primary hyperparathyroidism.
To highlight the role of calcimimetic agents in managing this condition.

Main Methods:

Review of established and novel pharmacological agents for primary hyperparathyroidism.
Discussion of the mechanism of action for calcimimetic agents.

Main Results:

Oral phosphate, bisphosphonates, and estrogens have demonstrated efficacy in managing primary hyperparathyroidism.
Calcimimetic agents represent a significant advancement by directly inhibiting parathyroid hormone secretion.

Conclusions:

Medical management is a viable option for select patients with primary hyperparathyroidism.
Calcimimetic agents provide a new therapeutic avenue for controlling parathyroid hormone levels and hypercalcemia.

Related Experiment Videos